Seeking Alpha
We cover over 5K calls/quarter
Profile| Send Message|
( followers)  

NuVasive, Inc. (NASDAQ:NUVA)

Barclays Global Healthcare Conference

March 12, 2013 9:00 am ET

Executives

Quentin Blackford

Stephan Ogilvie - Vice President of Corporate Development & Investor Relations

Unknown Analyst

Okay, so moving right along, we have our third session for the morning and really pleased to have NuVasive joining us. We have Quentin Blackford who's the Senior VP of Finance and Treasury and also Steve Ogilvie with us today from business development and IR. And so really pleased to have with you guys joining us.

Quentin Blackford

Thanks for having us.

Question-and-Answer Session

Unknown Analyst

Want to discuss a number of things. I think what's been really interesting is that you had struggled in Q3 but were able to bounce back really quickly and have talked about how you've been adding some sales personnel, but also just had a good showing at NAS and some new products that's been able to rejuvenate some of your business performance. And so maybe if you want to start there and kind of lay out the framework for the year and how should we think about the growth in 2013.

Quentin Blackford

Sure. So let's talk about Q3, Q4 a bit. Certainly coming off the third quarter that we had, we saw a bit of activity there that caught us by surprise towards the end of the quarter. We talked about that a bit on the Q3 call. We had some activity related to PODs where surgeons had exited for that to pursue that business model. Then we had some opportunities that surgeons took advantage of pursuing with relative to design deals with competitors, right? So we saw some of those things play out during the course of the quarter that we haven't fully anticipated. And going into the fourth quarter, we also were in a position of the sales reps being down roughly 14 positions over the course of the quarter. During Q4, we did step up efforts pretty significantly from a hiring perspective. We were able to offset that. We brought in 18 net representatives over the course of the quarter, so we more than offset what we saw, I believe, in Q3. But I don't really attribute a lot of the growth or the strength that we saw in the fourth quarter to those sales rep hires. It takes a while to bring those folks on board, train them, get them certified from an excellent perspective and really make them productive for us. When you look at the fourth quarter, I think what you saw was really -- underneath the results was a lot of strong procedural growth, right, more than anything else across the entire segment. You can look at lumbar, biologics, cervical, international, the entire portfolio is very strong. And when you look at we focused on during the course of the fourth quarter, there's a couple of things that took place. One, we took the opportunity to take the sales structure within the NuVasive organization and broke it into a domestic and international sales organization. We put new leadership amongst both of those teams. And now those were individuals that came into the organization. They've got a long track record of demonstrated success, have been very successful along the way in building international organizations, as well as domestic organizations. So that was the first change that we saw take place over the course of the quarter. We also had the opportunity to ramp out -- ramp up some incremental tools that we put into the hands of the sales force, and the way to think about that is mobility-type tools. So think of it as iPads, if you will, in their hands where they have access to marketing materials on a real-time basis, promotional material on a real-time basis. They're able to share cases across the entire sales organization. Now that they might go into or come out of where they've dealt with a particular issue, they can share that across the organization now. We've automated a lot of the administrative type of activities that they would go through. So things like charge sheets where they would call in to customer service and submit an order or bill the hospital, that's all done automatically now. And what happens with that is it really increases their ability to focus on the selling process versus the administrative types of things. I think that's what we saw play out during the course of the fourth quarter. You mentioned NAS. Now NAS was certainly a highlight for us. We were able to highlight our Precept system, which we're extremely excited about. We saw a very strong fourth quarter and we'll talk about that a bit more. PCM, where we got PMA approval to enter into the Motion Preservation segment of the cervical spine. So we saw some things come together on the product side as well. But there was a lot of things that came together over the fourth quarter that generated the strength and that result.

Unknown Analyst

And then this year, you laid out your guidance. You're calling for conservative numbers in lumbar relative to what you did in 2012 and a little bit of pickup from new products in Japan and PCM. Can you talk about some of those moving parts and how you see the dynamics in the spine market this year in terms of volumes and pricing and some of those areas that investors have been focused on?

Quentin Blackford

We see the overall market as being relatively flat as we head into 2013, which is pretty consistent with what we saw over the course of 2012. I think if you look back at Q4, you might have bit -- seen a bit of strength play out in the fourth quarter. I think it's still a bit early to really tell how that's going to play into the future. So from our perspective, when we put together our guidance, we looked at 2013 playing out essentially in line with the way we saw '12. So when you look at our guidance, we guided to $655 million, which is roughly 6% growth in the total business. When you really break out some of the contributors that we've called out, which was Japan roughly $10 million over the course of the year, we talked about our PCM product contributing roughly $3.5 million to $5 million, you come back into a U.S. lumber growth that's somewhere right around 3% -- 2% to 3%, which would still be in excess of where we had the market pegged, which is very low-single digit, flattish, call it, right? So our guidance certainly contemplates what we saw in Q3 playing out over the course of the full year. We talked about some of things we did in the fourth quarter and try to offset that. But from our perspective, we're trying to take a prudent approach to the way we look at 2013 and not get ahead ourselves in terms of how we're going to be able to combat some of the churn and the issues we saw play there ahead up in Q3. Until we get several quarters down the road and see our effectiveness at being able to offset that, we're not going to get in front of ourselves. So '13 certainly is a prudent approach, from our perspective, to how we look at the business. That's the domestic business. We talked about Japan a bit. We are expecting up to $10 million of contribution from the Japanese market. We don't play in Japan today. As a matter of fact, we did our first 2 XLIFs about 1.5 weeks ago there so we are now into that market. But prior to 2013, we really hadn't played there in a significant way. So Japan is the second largest spine market in the world, $400 million to $500 million of opportunity there that we just haven't had an access to get into there. We now have the only lateral opportunity or offering on the marketplace. So we think there's tremendous runway in front of that opportunity. The $10 million we expect that's going to be probably more back-end loaded. There's a significant training curve that's going to come with those surgeons. They haven't been privy to the lateral approach, right? So now you're training them for the first time. And the demand has been incredible. I mean, we've been training surgeons now since late Q4 all the way through Q1, very high demand there. Expect to see some very positive things come out of it, but again probably more back-end loaded. PCM is another new product opportunity that we think has a tremendous amount of potential. We'd guided $3.5 million to $5 million worth of contribution. Again, I think most of that comes towards the latter part of the year. There's a training curve associated with that as well. But when you look at PCM, which is our Motion Preservation device, it's getting us access into $100 million market, right, in terms of Motion Preservation within the cervical spine. And we think that market's growing anywhere from 20% to 25% and over time, believe that it may become the standard of care for cervical procedures, right? So while the overall spine market may not be growing all that fast, there's a lot of things happening underneath the spine market that are moving in, what we think, is our favor when it comes to minimally invasive spine surgery. We haven't had the opportunity to talk about the MIS shift yet, which we can talk about, but I think PCM is something that plays in a similar way where underneath the market there's a shift in the mix that's playing to our benefit.

Unknown Analyst

You mentioned Japan and o U.S. has been growing a lot for you. You're mainly U.S.-centric these days. But what does the Japan number imply for the rest of your growth o U.S.? And how should we think about the different geographies? Have you been experiencing any impact from European pressures? And how are you growing there versus other areas?

Quentin Blackford

Yes, so if you look at our international growth figure that we contemplated in guidance, it was roughly 35% growth. That included the $10 million contribution coming from Japan. So if you were to back out Japan, you'd be left with roughly 17%, 18% growth coming out of our international business. Certainly, we have felt the pressures within Europe. We've had to take the position in several markets to essentially pull back in what we've been doing there. We've got a hard time getting paid in a couple of those markets where most were distributor channels, but we've moved to more of a prepayment type of a model where they just haven't been able to invest this heavily. And that really is the result of the challenges we faced with them historically where we just, again, weren't able to get paid and realized the revenue that we were selling into those countries. So we had to change the approach there. So that certainly had an impact on our growth rate. And we've had to take a prudent approach to how we do business with those folks as we head into the future as well. Asia is a big opportunity for us. We've mentioned Japan. Australia continues to be a big opportunity. We were in Australia 3.5, 4 years ago. Underneath the leadership that we were able to bring in who's also leading the efforts into Japan, we've grown our position there to the #2 market position in about 3.5 years. So we're excited about what we have there. But certainly, as you get closer to that #1 position, the opportunity to continue to grow at the same pace is somewhat less than great but there's still significant opportunity. And I think what we've done in Australia speaks a bit to what we hope to do in Japan as well. Latin America is another opportunity for us. That's a healthy business, but again, most of that is through a distributor channel. We aren't direct there in any markets really outside of Puerto Rico, although Puerto Rico has been very strong for us. We have a #1 position in Puerto Rico as well. But for the most part, where you're going to see the majority of that growth is going to come out of Asia and Europe over the next several years.

Unknown Analyst

And you mentioned some of the trends that you've seen and the conservatism that you're using there to forecast, can you talk about some of those dynamics in terms of poaching and PODs and how you're able to counterbalance that and contemplate that in terms of looking at growth going forward?

Quentin Blackford

Yes, one of the things I hadn't hit on yet relative to a stepped up effort in Q4 was what we have in place called the NUVA Touch program, which is really -- it's getting our executives out into the field on a quarterly basis, engaging with our top surgeon customers, right? We want to be closer to those folks, understanding what are the issues they're dealing with on a daily basis. How can we better partner with them? How can we improve their daily operation and ultimately improve the outcomes of the patient that they're serving? And we believe that getting closer to them certainly has the opportunity to make us more aware of when these types of potential opportunities where they pursue a different avenue doesn't surprise us to the extent that it did in Q3, right? So we want to be much closer to the customer and we've ramped up those efforts. PODs are certainly something that have been prevalent in the marketplace for a while now, right? I think, from our perspective, we estimate they probably represent roughly 15% of the overall market. We understand why a surgeon potentially engages in that model. I mean, given the pressure in the marketplace from a pair of pushback perspective, they're looking at alternative ways to potentially replace income streams that have been there historically that are going away, right? So we understand a bit of why they would look into the model. But from our perspective, there's a significant ethical dilemma associated with that, right? When you start to introduce the financial outcome with patient outcomes, in our mind, that introduces that ethical challenge that we believe just doesn't belong in a marketplace. What we've done, from our perspective, is really try to educate the hospitals on exactly what that dilemma is. And what we're finding is when a hospital has learned more about those POD models, they're generally pretty receptive to the fact that there is an ethical challenge there. They understand it, and we've seen progress there, sharp health care, scripts health care out of California. Both have taken positions where they won't allow POD-sourced products into their practice. I've heard that the workers' comp cases in California as well will not be reimbursed if they're utilizing POD-sourced products. Now HCA, who's a buying group, has stepped up efforts to where they won't allow POD-sourced products in there either. And we know the OIG has put out questionnaires as well to the surgeon community, trying to gather more information how the POD model works. So there's more awareness around there. Certainly, it's becoming something that people are paying attention to. But the pressure is continuing to exist. I mean, from our perspective, until that model is reviewed and potentially modified, the best we can do is get out there and educate on the role that it brings into the marketplace, and we're certainly trying to do what we can there.

Unknown Analyst

Maybe we can pause a bit. We'll the ask the audience a question about your upside this year. So can we queue up the first question for the audience? So getting to punch in on your handheld, what you think NuVasive's greatest potential source of upside in 2013 and, say, the PCM, Japan, AttraX approval, lumbar market growth or share gains?

[Voting]

Unknown Analyst

And so it looks like it's kind of a tie between Japan and lumbar market growth and AttraX approval there. We didn't talk about AttraX yet, I don't know if I want to discuss that all and what the implications are there from a margin standpoint and a differentiation standpoint.

Quentin Blackford

Sure. We did talk about it. Our guidance certainly does not contemplate any contribution coming from AttraX within the domestic market, right, except from a U.S. perspective. We continue to work with the FDA on that product in terms of getting approval. It's been something that's been in the FDA -- or with the FDA for several quarters now, well over a year, probably approaching 2 years. And at this point, it continues to have an uncertain future. I mean, we continue to work with the FDA, provide data, they come back and seem to want to look at it a bit differently and ask for more data, right? So we continue to engage with them down that path, but we don't have any more information to share with you relative to an anticipated approval date at this point in time. But I would make clear, it's not in the guidance today. So certainly, any approval that we would get would give us some opportunity on the upside to generate some incremental revenue. Now AttraX is a product that we're very interested in. I mean, it gives us a synthetic product offering that brings economic profile with -- that's very much better than what we see in our Osteocel Plus product today. So our biologics products generally have their gross margin profile of somewhere around the 70% margin. AttraX is certainly well north of that. So certainly, while it opens up a new opportunity to sell into, from a market perspective, it brings with an economic profile that's much more beneficial to us as well. So really look forward to getting it approved. I can tell you internationally, it's had some strong success, very well received. This is the best. We haven't been able to get it through.

Unknown Analyst

We'll take another one to the audience. I'm curious to see what people think about this one. So talked about your lumbar guidance this year, and the question is, what do you expect NuVasive's lumbar business to grow in 2013? I think this is really a U.S. question. So guidance is around 2%.

Quentin Blackford

2%, as I mentioned.

Unknown Analyst

So about 4% -- 2% to 4% or 2%, 0% to 2%, down 2% to flat or a decline of more than 2%?

[Voting]

Unknown Analyst

Okay, so it looks like you're getting a little credit there for conservatism. Do you think, in terms of your lumbar growth, the biggest dynamic change that could lead you to higher than your guidance would be some improvement in the market or improvement in share gains?

Quentin Blackford

There's no question, improvement in the market certainly is going to benefit the tide here, right? I think the one thing we haven't had an opportunity to really talk about yet that's important to realize is even though the overall lumbar market is growing, call it roughly flat, domestically, within the market itself is a shift towards minimally invasive spine surgery, right? So the way we look at it today is probably, a year ago, probably 80% of procedures were done through a traditional approach coming in from the anterior, posterior aspect. Today, in 2012, a year later, we think that's probably shifted down to roughly 75%, meaning the other 25% are done through a minimally invasive approach. NuVasive is the market share leader when it comes to minimally invasive spine surgery. And you're starting to see data come together and research come together, that really proves the value of a minimally invasive approach, right? I mean, from a clinical perspective, patients do much better. Blood loss is significantly lower. The recovery times are faster. Fusion rates can be better. So from a clinical perspective, certainly, there's benefits but we're also starting to see the economic benefits as well, right? We've seen studies done by a few different surgeons demonstrating the XLIF is 10% cheaper in a single level case as much as 14% cheaper in a 2-level case. It's that research that I think is going to put us in a position to potentially drive share gains over the long run even without the overall market growing. So certainly, the market growth is going to contribute to the ability to drive a growth rate in excess of what we guided to if it rebounds right, if the market is stronger. But as well, within the market itself, I think there's an opportunity where we see MIS starting to play out. As research and data becomes more prevalent out there, people start to understand that value. So I think there's another opportunity there. It's just shared gains and how we see minimally invasive spine surgery playing out over the next several years. I think both of them probably provide some potential upside to the opportunity to drive that to the extent that we're able to take that share.

Unknown Analyst

One area we didn't talk about in terms of the market, it's been a favorite topic of The Street over the last couple of years, is pushback from payers. Are you seeing any change there? Or is it somewhat consistent in terms of pushing back on some of the things that may not be indicated by the Milliman Guidelines?

Quentin Blackford

Guidelines. Sure. Yes, there's no question that the pressure continues to be prevalent in the marketplace. I would say it's been pretty consistent over the last several quarters, about 1 year, 1.5 years now. What we've tried to do is, and we believe that the best way to combat this, is with data, right? And we rally the surgeon community together to try to formulate what we call an HTA or a health technology assessment, which essentially looks at all the data out there relative to fusion procedures, particularly those in degenerative disc disease cases, which is where you're seeing the majority of the payer pushback coming from. And articulate the value of a fusion procedure in those indications, right, and then we've finally seen that come together. So the HTA has been published. It'll be more widely published in Spine Magazine in April. We think that's the first real step forward in being able to combat this. Now from that HTA, what needs to happen is the surgeon societies need to come together and formulate a set of guidelines similar to the Milliman Guidelines but now it's actually based on clinical outcomes, right, on data, get those surgeon societies to formulate those guidelines and then present those to the payers. And we think that's where you start to see the real effective combating of the payer pushback that we see today and hopefully, replace the Milliman Guidelines with clinical-based evidence that demonstrate the value of fusion procedures. So I think we're heading down the right path. I think we're still a ways off before we see those guidelines in place. But I think that's going to be the most effective means of being able to do that.

Unknown Analyst

Let's talk a little bit about margins because you're focused now on more profitable growth and so you grow towards being a $1 billion company. Can you talk about some of the improvement programs that you're putting in place to be able to drive that more profitable growth and your margin expectations over the next couple of years?

Quentin Blackford

Sure. So we've talked -- as an organization, we kind of look at where we're at today and our guidance contemplates a 14% operating margin contribution, which includes the medical device tax, roughly 150 basis points of impact. So that is better than the 14%. We've said as we approach $1 billion as a company, we want to see that operating margin moving towards 20% and right into the low 20s. When you look at the opportunities there, I think what folks need to appreciate is the fact that since we've entered into the international space, we've chosen to do that in a direct manner, meaning we want to be direct in most of the markets that we're represented in for the most part, right? And there's a big investment associated with that, Japan is a great example. For the last several years, we've been investing heavily in the regulatory process, right, to get the product approved, right? And then as we get approval, building out the infrastructure from a distribution channel. How do we get that put in place and you can -- and it's kind of the same process with each of the other markets we've been in. So o U.S. has been a big investment cycle for us over the last several years. We're now getting to the point where o U.S. is breakeven as it came out of 2012. And as we look forward into the future, we think that becomes a big leverage opportunity in terms of profitability. So as we approach $1 billion, we expect international o U.S. to be roughly $200 million of that $1 billion, right? And we expect it to have an operating margin profile that's in excess of the corporate average. So if we're thinking of the corporate average being around 20% at $1 billion, we want to see o U.S. in excess of 20%. That's coming off of a profile today that's roughly breakeven, right? So there's significant leverage opportunities in just the o U.S. business. The other thing is manufacturing capabilities. We don't manufacture nearly anything that we sell in-house today. We're exploring different opportunities to bring that in-house. There's competitors out there. If you were to benchmark ours against them and just look at our product cost, for instance, there's as much as 500 basis points of difference between the 2 companies, 2 or 3 companies that you look at, right? So I'm not saying that we'll deliver 500 basis points of our gross margin expansion, but that's certainly speaks to the potential opportunity, right? It's somewhere between 0 and 500. So there's significant opportunity within the manufacturing side as well. I think you just look at some of the other investments that we've made, whether it be IT systems that we can start to grow into that you may have invested a bit ahead of the curve so we're now in a position that we can grow into those and drive leverage out of them. There's certainly opportunities in the U.S. sales force where we can drive efficiencies as they become more tenured with the organization. They dive deeper into the existing accounts that they have and gave more of the -- they might have the XLIF for the lateral procedure today. How can we get the cervical? How can get all the biologics, right? How can we get all the posterior fixation? Let's associated with those procedures? Those are the kind of things we're focused on that I think it's going to drive leverage out of the model. And certainly, we believe getting from 14% to 20% as we approach $1 billion is -- that's 600 basis points of operating margin improvement. We see a clear path to get there. We believe it's very much attainable.

Unknown Analyst

You guys talked about the capital deployment and then maybe we can talk a little bit about your use of cash. But let's ask the audience a question in terms of what they think NuVasive should do with excess cash, the bolt-on M&A, larger M&A, buybacks, dividends, internal investment or debt paydown?

[Voting]

Unknown Analyst

So buyback seems to be the winner but we've got pretty even distribution over the other one. Do you want to talk a little bit about your current capital plan?

Quentin Blackford

Sure. I mean, from our perspective, we still believe there's several M&A opportunities out there that drive tremendous value in the business. And I think we certainly have shifted a bit in how we look at M&A. We're going to be less likely to take on projects that are going to have significant risk associated with them. So think of that as products you're going to have to move through the FDA from a PMA perspective, right? We're not likely to head down that path at this point in time. There's just too much uncertainty and risk associated with that, but we're still interested in things that have more of a certain outcome. And the way I think of that is we talked about manufacturing, how can we bring more of that in-house, right? There's certainly the opportunity to drive some operational effectiveness or improvements associated with that opportunity. In addition to that, we're looking at a tax strategy, right, from an international perspective. Manufacturing can kind of team up with that tax strategy in a pretty effective way to where they can drive some significant financial leverage. So we're focused on those type of opportunities, focused on how can we expand our international footprint, right? How can we ramp the o U.S. business faster? I mean, if you look at our o U.S. business today, it's roughly 10% of the overall business, right? We talked about $1 billion. We're going to see it upwards of 20%. But if you look a lot of the competitors out there that are larger than $1 billion, they have as much as 30%, 35%, 40% of their business being generated through international channels. There's certainly opportunity there to continue to expand that. So we're looking at things like expanding the o U.S. footprint. Now if we were to do something on a product side, it certainly would be some of the products that's already been developed, right, or at least moving down the 510(k) pathway, something with less risk associated with it. I don't know if you would add anything to that but...

Stephan Ogilvie

No, the one thing that I'd say is the reason NuVasive has grown historically is that we're pushing the world toward minimally invasive surgery and so that's been the growth driver and continues to be. There's these opportunities in M&A to do bolt-on things and I think you've seen that from us historically. But the main growth engine that NuVasive has is training doctors to learn how to do minimally invasive surgery. I mean, we have hundreds of doctors that want come to us and with the earlier questions, a trick for us is to retain them. In the uncertainties and complications of the spine market right now, that's the trick. There's definitely demand to move to MIS so we have the best offering out there. We're the market share leaders. It's holding on to that share that's really going to drive it for us.

Unknown Analyst

And we're almost out of time but maybe one last one on litigation. So you recently released some capital from the trademark litigations. That was certainly a positive and you still have some -- the Medtronic litigation. You talked about upcoming royalty expectations. Do you want to give an update there in terms of overview and how to think about the impact of that over the next 6 to 12 months?

Quentin Blackford

Yes, certainly. So from a Medtronic litigation perspective, we are currently accruing to the royalty rates that essentially the jury used in their verdict, right? That's that the best information that we could get a hold of but it implied roughly a 10% royalty rate on the CoRoent implant and 2% to 3% on the cervical implants in the retractor system. Those rates were not formally settled by the court, right? And essentially, they passed on to appellant process and then we're going to wait for those rates to be determined there. What has happened is the appeals court has said, before we're going to hear that case, we want those rates set, right? So they kicked it back to the trial court. There's a new judge on the case. She's been -- I guess, there's a tremendous amount of work on her plate. As we talk with her, I think she's been a bit surprised, not necessarily by the case that we brought to her, but by the entire workload she's dealing with. And she just hasn't been able to get to our case at this point in time. So there's no further clarity that I can give you relative to where we expect that rate to land from our perspective. The rates we're using is the best information that we have, right? I mean, if we had anything different, we would be utilizing those rates. But at this point in time, we're waiting for her to rule on what those rates will be and then we'll head down the appeals process, which will probably take upwards of 12 months or so once we get into that process. But in terms of the rates themselves, I can't give you any more information than where we're at today. That's the best information that we currently have available. We expect to hear something back from her. We've been saying we thought Q4 -- we've been engaged with her and having discussions with her but she hasn't given us an indicated time line. So I would say sometime over the next 60, 90 days or so. But that's we're speculating at this point.

Unknown Analyst

Great. Well, thanks for your time. I think we will stop.

Quentin Blackford

Thanks, guys.

Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.

THE INFORMATION CONTAINED HERE IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL, CONFERENCE PRESENTATION OR OTHER AUDIO PRESENTATION, AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION, THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE AUDIO PRESENTATIONS. IN NO WAY DOES SEEKING ALPHA ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S AUDIO PRESENTATION ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

If you have any additional questions about our online transcripts, please contact us at: transcripts@seekingalpha.com. Thank you!

Source: NuVasive's Management Presents at Barclays Global Healthcare Conference (Transcript)
This Transcript
All Transcripts